IL33 and melanoma: Systemic administration of recombinant IL-33 protein could inhibit growth of established tumors in transplant and de novo melanoma tumorigenesis models through inducing CD8 T cell expansion and IFN-γ production, as well as through restoring dendritic cell activation and maturation [66].